Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
ML 145 acts as a competitive antagonist for a number of agonists at human GPR35 and has an IC50 value against EC80 concentrations of various GPR35 agonists in the region of 20 nM
Discovery and Development of LX7101
InChi: InChI=1S/C18H14F3N3O4S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)28-12-4-6-13(7-5-12)29-18(19
58 μM) and norepinephrine transporter (NET) (IC50=0
ClH/c22-6-7-29-8-9-30-10-11-31-12-13-32-16-3-1-2-14-18(16)21(28)24(20(14)27)15-4-5-17(25)23-19(15)26
PS10 aptomycin ML 145 acts as aPS10 is a novel, potent and ATP competitive pan PDK inhibitor, inhibits all PDK isoforms with IC50 of 0. 8 M, 0. 76 M, 2. 1 M and 21. 3 M for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (Kd= 239 nM) than for Hsp90 (Kd= 47 M). PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy. PDK: pyruvate
US$ 187.00
US$ 138.00
US$ 147.00
US$ 106.50
US$ 295.00
US$ 138.00
US$ 217.50